Pharmacological predictors of heart rate and conductivity disorders in juvenile myoclonic epilepsy

Shnayder, Natalia A.; Петрова, М. М.; Petrov, K. V.; Насырова, Р. Ф.

doi:10.17749/2077-8333/epi.par.con.2021.051

Cited by 3 publications

(4 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The problem of drug-induced LQTS was a discussion topic at the 2005 International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). This led to the adoption and publication of recommendations on the evaluation of elongation QT interval and proarrhythmic potential of non-antiarrhythmic drugs (ICH-E14) [86,87]. The study concluded that almost all APs, with a few exceptions, should undergo a "thorough QT study" (TQT), as defined by ICH-E14.…”

Section: Discussionmentioning

confidence: 99%

“…The latter group was further subdivided into class B* drugs (Table 5). APs that are best avoided in patients with congenital QT interval prolongation, with a conditional risk of TdP, and those with a known risk of TdP were compiled into class B* [2,87,88]. LQTS is an important risk factor for the development of TdP, which, in turn, can lead to ventricular fibrillation and SDS [89].…”

Section: Discussionmentioning

confidence: 99%

“…LQTS is an important risk factor for the development of TdP, which, in turn, can lead to ventricular fibrillation and SDS [89]. The relationship between AP-induced LQTS and TdP frequency is not direct [87,90,91], since many factors and comorbid conditions can increase or decrease the risk of these iatrogenic effects [90,[92][93][94]. The analysis of first and new generation APs currently used to treat Sch, and many years of experience in our own clinical practice, indicate that there is no completely safe medication, i.e., no APs can be properly assigned to category A [95].…”

Section: Discussionmentioning

confidence: 99%

“…Classification of psychotropic drugs according to the risk of QT prolongation interval and the development of arrhythmias[87,88].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia

Vaiman

Shnayder²,

Zhuravlev³

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Antipsychotics (AP) induced prolongation of the QT interval in patients with schizophrenia (Sch) is an actual interdisciplinary problem as it increases the risk of sudden death syndrome. Long QT syndrome (LQTS) as a cardiac adverse drug reaction is a multifactorial symptomatic disorder, the development of which is influenced by modifying factors (APs’ dose, duration of APs therapy, APs polytherapy, and monotherapy, etc.) and non-modifying factors (genetic predisposition, gender, age, etc.). The genetic predisposition to AP-induced LQTS may be due to several causes, including causal mutations in the genes responsible for monoheme forms of LQTS, single nucleotide variants (SNVs) of the candidate genes encoding voltage-dependent ion channels expressed both in the brain and in the heart, and SNVs of candidate genes encoding key enzymes of APs metabolism. This narrative review summarizes the results of genetic studies on AP-induced LQTS and proposes a new personalized approach to assessing the risk of its development (low, moderate, high). We recommend implementation in protocols of primary diagnosis of AP-induced LQTS and medication dispensary additional observations of the risk category of patients receiving APs, deoxyribonucleic acid profiling, regular electrocardiogram monitoring, and regular therapeutic drug monitoring of the blood APs levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Classification of psychotropic drugs according to the risk of QT prolongation interval and the development of arrhythmias[87,88].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia

Vaiman

Shnayder²,

Zhuravlev³

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

The role of DNA-profiling in predicting anticonvulsant-induced QT prolongation diseases based on pharmacogenetic aspects

2023

Self Cite

View full text Add to dashboard Cite

Anticonvulsants or antiepileptic drugs (AEDs) are widely used for various neurological and psychiatric diseases and are often prescribed for a long period. In this regard, the issue of their safety profile is acute, including risk assessment for the development of life-threatening conditions and adverse drug reactions (ADRs). From the point of view of personalized medicine, it is important to develop an interdisciplinary approach to the development of a new strategy for a personalized approach to predicting AED-induced prolongation of the QT interval as one of the most unfavorable prognostic cardiac ADRs (including sudden death syndrome — SDS). We searched the databases of full-text publications for the period from 2012 to 2022 for keywords and their combinations. We have discovered and systematized monogenic and multifactorial forms of long QT syndrome (LQTS) and candidate genes that slow down AEDs metabolism in the liver. Identification of risk alleles of single nucleotide variants (SNV) of candidate genes predisposing to the development of AED-induced LQTS and SDS will allow adjusting the choice and dosage of these drugs and preventing the development of the ADR, which will improve the quality of life and help prevent SDS in patients with mental and neurological disorders

show abstract

Interindividual Variability of Anticonvulsant-Induced QT Prolongation Risk

Zhuravlev¹,

Shnayder

Vaiman³

et al. 2022

jour

View full text Add to dashboard Cite

In connection with the widespread use of anticonvulsants (antiepileptic drugs – AEDs) in psychiatric and neurological practice and the need for their long-term use to treat a wide range of mental disorders and neurological diseases, the question of their safety profile, including the assessment of the risk of developing life-threatening conditions and adverse reactions (ADRs), becomes relevant. In this regard, from the position of personalized medicine, it is critical to develop an interdisciplinary approach with the participation of doctors of various specialties and a new strategy of a personalized approach to predicting AED-induced prolongation of the QT interval as one of the most prognostically unfavorable cardiological ADRs (including sudden death syndrome – SDS). We searched for full-text publications for the period from 2011 to 2021 databases using the following keywords and its combination. We have found and systematized monogenic and multifactorial forms of long QT syndrome (LQTS) and candidate genes that slow down AEDs metabolism in the liver. Identification of risk alleles of single nucleotide variants (SNVs) of the candidate genes predisposing to the development of AED-induced LQTS and SDS will make it possible to adjust the choice and dosage of these drugs and prevent the development of ADRs, which will improve the quality of life of patients and prevent SDS in the patients with psychiatric and neurological disorders.

show abstract

Pharmacological predictors of heart rate and conductivity disorders in juvenile myoclonic epilepsy

Cited by 3 publications

References 67 publications

Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia

Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia

The role of DNA-profiling in predicting anticonvulsant-induced QT prolongation diseases based on pharmacogenetic aspects

Interindividual Variability of Anticonvulsant-Induced QT Prolongation Risk

Contact Info

Product

Resources

About